Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Provided By PR Newswire
Last update: Nov 5, 2024
- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS
- Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS
